{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:21:03Z","timestamp":1790014863560,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"National Institute of Allergy and Infectious Diseases (US)","award":["R21\/R33 AI122377-01"],"award-info":[{"award-number":["R21\/R33 AI122377-01"]}]},{"name":"National Heart, Lung, and Blood Institute (US)","award":["R01 HL126547"],"award-info":[{"award-number":["R01 HL126547"]}]},{"name":"National Center for Advancing Translational Sciences (US)","award":["1KL2TR001065"],"award-info":[{"award-number":["1KL2TR001065"]}]},{"name":"Doris Duke Charitable Foundation (US)","award":["2016102"],"award-info":[{"award-number":["2016102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Retrovirology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12977-016-0319-0","type":"journal-article","created":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T06:50:50Z","timestamp":1482216650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1815-7893","authenticated-orcid":false,"given":"Adam M.","family":"Spivak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin T.","family":"Larragoite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"McKenna L.","family":"Coletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda B.","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Planelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,20]]},"reference":[{"issue":"15","key":"319_CR1","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1073\/pnas.95.15.8869","volume":"95","author":"TW Chun","year":"1998","unstructured":"Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA. 1998;95(15):8869\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5341","key":"319_CR2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295\u2013300.","journal-title":"Science"},{"issue":"5341","key":"319_CR3","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","volume":"278","author":"JK Wong","year":"1997","unstructured":"Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278(5341):1291\u20135.","journal-title":"Science"},{"issue":"18","key":"319_CR4","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1097\/QAD.0b013e328340a239","volume":"24","author":"TW Chun","year":"2010","unstructured":"Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS. 2010;24(18):2803\u20138.","journal-title":"AIDS"},{"issue":"7408","key":"319_CR5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","volume":"487","author":"SG Deeks","year":"2012","unstructured":"Deeks SG. HIV: shock and kill. Nature. 2012;487(7408):439\u201340.","journal-title":"Nature"},{"issue":"5","key":"319_CR6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/infdis\/jiu155","volume":"210","author":"NM Archin","year":"2014","unstructured":"Archin NM, Bateson R, Tripathy MK, Crooks AM, Yang KH, Dahl NP, et al. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J Infect Dis. 2014;210(5):728\u201335.","journal-title":"J Infect Dis"},{"issue":"5","key":"319_CR7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1468-1293.2011.00975.x","volume":"13","author":"JP Routy","year":"2012","unstructured":"Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012;13(5):291\u20136.","journal-title":"HIV Med"},{"issue":"7408","key":"319_CR8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"NM Archin","year":"2012","unstructured":"Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487(7408):482\u20135.","journal-title":"Nature"},{"issue":"1","key":"319_CR9","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","volume":"1","author":"TA Rasmussen","year":"2014","unstructured":"Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial. Lancet HIV. 2014;1(1):e13\u201321.","journal-title":"Lancet HIV"},{"issue":"6","key":"319_CR10","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/cid\/cit813","volume":"58","author":"AM Spivak","year":"2014","unstructured":"Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis. 2014;58(6):883\u201390.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"319_CR11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.molmed.2015.11.004","volume":"22","author":"AM Spivak","year":"2016","unstructured":"Spivak AM, Planelles V. HIV-1 eradication: early trials (and tribulations). Trends Mol Med. 2016;22(1):10\u201327.","journal-title":"Trends Mol Med"},{"issue":"5","key":"319_CR12","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1172\/JCI80142","volume":"125","author":"GM Laird","year":"2015","unstructured":"Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Investig. 2015;125(5):1901\u201312.","journal-title":"J Clin Investig"},{"issue":"5","key":"319_CR13","doi-asserted-by":"crossref","first-page":"e97257","DOI":"10.1371\/journal.pone.0097257","volume":"9","author":"CM Abreu","year":"2014","unstructured":"Abreu CM, Price SL, Shirk EN, Cunha RD, Pianowski LF, Clements JE, et al. Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS ONE. 2014;9(5):e97257.","journal-title":"PLoS ONE"},{"issue":"11","key":"319_CR14","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/QAD.0000000000000289","volume":"28","author":"G Jiang","year":"2014","unstructured":"Jiang G, Mendes EA, Kaiser P, Sankaran-Walters S, Tang Y, Weber MG, et al. Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase C\u03b4\u2013NF\u2013\u03baB signaling. AIDS. 2014;28(11):1555\u201366.","journal-title":"AIDS"},{"key":"319_CR15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.virol.2014.05.033","volume":"462\u2013463","author":"D Pandelo Jose","year":"2014","unstructured":"Pandelo Jose D, Bartholomeeusen K, da Cunha RD, Abreu CM, Glinski J, da Costa TB, et al. Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology. 2014;462\u2013463:328\u201339.","journal-title":"Virology"},{"issue":"2","key":"319_CR16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13555-014-0061-2","volume":"4","author":"DR Alchin","year":"2014","unstructured":"Alchin DR. Ingenol mebutate: a succinct review of a succinct therapy. Dermatol Ther. 2014;4(2):157\u201364.","journal-title":"Dermatol Ther"},{"key":"319_CR17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jep.2015.10.025","volume":"176","author":"M Ernst","year":"2015","unstructured":"Ernst M, Grace OM, Saslis-Lagoudakis CH, Nilsson N, Simonsen HT, Ronsted N. Global medicinal uses of Euphorbia L. (Euphorbiaceae). J Ethnopharmacol. 2015;176:90\u2013101.","journal-title":"J Ethnopharmacol"},{"issue":"10","key":"319_CR18","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1128\/AAC.01077-15","volume":"59","author":"AM Spivak","year":"2015","unstructured":"Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+ T Cells from Aviremic Patients. Antimicrob Agents Chemother. 2015;59(10):5984\u201391.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"319_CR19","doi-asserted-by":"crossref","first-page":"e1005063","DOI":"10.1371\/journal.ppat.1005063","volume":"11","author":"G Darcis","year":"2015","unstructured":"Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, et al. An In-depth comparison of latency-reversing agent combinations in various in vitro and ex vivo HIV-1 latency models identified bryostatin-1+JQ1 and ingenol-B+JQ1 to potently reactivate viral gene expression. PLoS Pathog. 2015;11(7):e1005063.","journal-title":"PLoS Pathog"},{"issue":"7","key":"319_CR20","doi-asserted-by":"crossref","first-page":"e1005066","DOI":"10.1371\/journal.ppat.1005066","volume":"11","author":"G Jiang","year":"2015","unstructured":"Jiang G, Mendes EA, Kaiser P, Wong DP, Tang Y, Cai I, et al. Synergistic reactivation of latent HIV expression by ingenol-3-angelate, PEP005, targeted NF-kB signaling in combination with JQ1 induced p-TEFb activation. PLoS Pathog. 2015;11(7):e1005066.","journal-title":"PLoS Pathog"},{"issue":"6","key":"319_CR21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2174\/157016210793499312","volume":"8","author":"M Perez","year":"2010","unstructured":"Perez M, de Vinuesa AG, Sanchez-Duffhues G, Marquez N, Bellido ML, Munoz-Fernandez MA, et al. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res. 2010;8(6):418\u201329.","journal-title":"Curr HIV Res"},{"key":"319_CR22","doi-asserted-by":"publisher","unstructured":"Gama L, Abreu CM, Shirk EN, Price SL, Li M, Laird GM, Pate KA, Wietgrefe SW, O'Connor SL, Pianowski L, Haase AT, Van Lint C, Siliciano RF, Clements JE, LRA-SIV Study Group. Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. AIDS. 2017;31(1):5-14. doi: 10.1097\/QAD.0000000000001267","DOI":"10.1097\/QAD.0000000000001267"},{"issue":"1","key":"319_CR23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/aid.2014.0199","volume":"31","author":"G Jiang","year":"2015","unstructured":"Jiang G, Dandekar S. Targeting NF-\u03baB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res Hum Retroviruses. 2015;31(1):4\u201312.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"40","key":"319_CR24","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.1074\/jbc.M402124200","volume":"279","author":"SA Williams","year":"2004","unstructured":"Williams SA, Chen LF, Kwon H, Fenard D, Bisgrove D, Verdin E, et al. Prostratin antagonizes HIV latency by activating NF-\u03baB. J Biol Chem. 2004;279(40):42008\u201317.","journal-title":"J Biol Chem"},{"issue":"17","key":"319_CR25","doi-asserted-by":"crossref","first-page":"9833","DOI":"10.1074\/jbc.270.17.9833","volume":"270","author":"EM Genot","year":"1995","unstructured":"Genot EM, Parker PJ, Cantrell DA. Analysis of the role of protein kinase C-alpha, -epsilon, and -zeta in T cell activation. J Biol Chem. 1995;270(17):9833\u20139.","journal-title":"J Biol Chem"},{"issue":"16","key":"319_CR26","doi-asserted-by":"crossref","first-page":"8118","DOI":"10.1128\/JVI.76.16.8118-8123.2002","volume":"76","author":"YD Korin","year":"2002","unstructured":"Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol. 2002;76(16):8118\u201323.","journal-title":"J Virol"},{"issue":"6611","key":"319_CR27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/385083a0","volume":"385","author":"CR Monks","year":"1997","unstructured":"Monks CR, Kupfer H, Tamir I, Barlow A, Kupfer A. Selective modulation of protein kinase C-theta during T-cell activation. Nature. 1997;385(6611):83\u20136.","journal-title":"Nature"},{"issue":"6776","key":"319_CR28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/35006090","volume":"404","author":"Z Sun","year":"2000","unstructured":"Sun Z, Arendt CW, Ellmeier W, Schaeffer EM, Sunshine MJ, Gandhi L, et al. PKC-theta is required for TCR-induced NF-\u03baB activation in mature but not immature T lymphocytes. Nature. 2000;404(6776):402\u20137.","journal-title":"Nature"},{"issue":"4","key":"319_CR29","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nm.3489","volume":"20","author":"CK Bullen","year":"2014","unstructured":"Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014;20(4):425\u20139.","journal-title":"Nat Med"},{"issue":"10","key":"319_CR30","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/blood.V98.10.3006","volume":"98","author":"J Kulkosky","year":"2001","unstructured":"Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood. 2001;98(10):3006\u201315.","journal-title":"Blood"},{"issue":"12","key":"319_CR31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117\u201327.","journal-title":"N Engl J Med"},{"issue":"25","key":"319_CR32","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377\u201386.","journal-title":"N Engl J Med"},{"issue":"6","key":"319_CR33","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00280-016-3012-z","volume":"77","author":"JC Bryan","year":"2016","unstructured":"Bryan JC, Verstovsek S. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Cancer Chemother Pharmacol. 2016;77(6):1125\u201342.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"319_CR34","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1086\/344357","volume":"186","author":"J Kulkosky","year":"2002","unstructured":"Kulkosky J, Nunnari G, Otero M, Calarota S, Dornadula G, Zhang H, et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis. 2002;186(10):1403\u201311.","journal-title":"J Infect Dis"},{"issue":"17","key":"319_CR35","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/00002030-199912030-00012","volume":"13","author":"JM Prins","year":"1999","unstructured":"Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, Schellekens PT, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS. 1999;13(17):2405\u201310.","journal-title":"AIDS"},{"issue":"12","key":"319_CR36","doi-asserted-by":"crossref","first-page":"e1003834","DOI":"10.1371\/journal.ppat.1003834","volume":"9","author":"CA Spina","year":"2013","unstructured":"Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, et al. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog. 2013;9(12):e1003834.","journal-title":"PLoS Pathog"},{"issue":"4","key":"319_CR37","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/AAC.02496-13","volume":"58","author":"C Gavegnano","year":"2014","unstructured":"Gavegnano C, Detorio M, Montero C, Bosque A, Planelles V, Schinazi RF. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother. 2014;58(4):1977\u201386.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Retrovirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-016-0319-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T02:21:15Z","timestamp":1498357275000},"score":1,"resource":{"primary":{"URL":"http:\/\/retrovirology.biomedcentral.com\/articles\/10.1186\/s12977-016-0319-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1186\/s12977-016-0319-0","relation":{},"ISSN":["1742-4690"],"issn-type":[{"value":"1742-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"article-number":"88"}}